SA
UTHR icon

Seneschal Advisors’s United Therapeutics UTHR Stock Holding History

Seneschal Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542 Hold
1
– – ﹤0.01% 380
2026
Q1 		$593 Hold
1
– – ﹤0.01% 327
2025
Q4 		$488 Hold
1
– – ﹤0.01% 364
2025
Q3 		$420 Buy
+1
New +$336 ﹤0.01% 406

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Seneschal Advisors's UTHR Position: Q2 2026 in Review

Seneschal Advisors held its United Therapeutics (UTHR) position steady in Q2 2026 at 1 share worth $542. The position accounts for ﹤0.01% of the portfolio, ranked #380.

Seneschal Advisors first reported a position in UTHR in Q3 2025 and has held it in 4 quarters since. The position peaked at $593 in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Seneschal Advisors held 1 share of United Therapeutics worth $542 as of Q2 2026.
  • Seneschal Advisors left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Seneschal Advisors's portfolio in Q2 2026, its #380 holding.
  • Seneschal Advisors first reported a position in United Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Seneschal Advisors's United Therapeutics position peaked at $593 in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Seneschal Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.